Premaitha strikes first Asia deal for IONA test
PIONEERING Manchester medical diagnostics company Premaitha Health has extended the reach of its IONA product with a deal to launch in India.
The AIM-listed company which has developed a non-invasive, quick and cost effective test for Down’s Syndrome and other conditions, has struck a deal with Vision Medical, a new organisation based in the UK and India that aims to deliver better diagnostic tests to the developing world.
At its office in Chennai Visional Medical works closely with obstetricians and midwives throughout India to raise awareness and improve education on the benefits of using (non-invasive pre-natal testing) NIPT and establish links with local hospitals and clinics. There are nearly 26 million births every year in India but many pregnant women do not have access to any form of prenatal screening. However, this is changing and the private market for NIPT is growing rapidly – especially in the country’s metropolitan areas.
Visional Medical will provide pregnant women in India access to the IONA® test to safely and accurately estimate the risk of a fetus being affected by serious genetic disorders, including Down’s, Edwards’ and Patau’s syndrome.
The IONA test only requires a sample of maternal blood to analyse cell-free fetal DNA and provide a result. Blood samples from these pregnant women will be sent to Premaitha’s CQC-registered clinical service laboratory in Manchester where they will be analysed using the IONAtest and the results sent directly to healthcare professionals in India.
Dr Stephen Little, chief executive of Premaitha said: “The potential market for NIPT in India is huge – there are millions of pregnancies every year and currently little provision of any prenatal screening. Our partnership with Visional Medical will provide a risk-free, rapid and reliable prenatal screening test to address this unmet medical need.
“This partnership also expands the geographical reach of Premaitha’s IONA test into Asia for the first time and marks the fourth such agreement that we have made with specialist regional partners in the past three months. As we continue to accelerate our global footprint and reach of NIPT with the IONA test, we can provide more expectant mothers with the benefits of using a safe, accurate and stress-free test.”
Dr Colin Ferrett, head of Visional Medical added: “We are thrilled to be working with Premaitha and we look forward to offering this advanced yet simple screening test to improve prenatal provision to the large population of pregnant mothers in India. Visional Medical’s mission is to work with cutting edge diagnostic tools to advance healthcare into the 21st century for the developing world.”
